Español
Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner eye tissue on which images are projected and where light signals are converted into electrical impulses reaching the brain and generating vision. It is described as the sudden loss of vision in one of the two eyes due to the […]
Author Archives: oligofastx
Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner eye tissue on which images are projected and where light signals are converted into electrical impulses reaching the brain and generating vision. It is described as the sudden loss of vision in one of the two eyes due to the […]
The last few years have been a true revolution in terms of discoveries and initiatives linked to the world of oligonucleotides, and all eyes and hopes continue to focus in the same direction in the new year 2023. It is clear that the research being carried out in the scientific world is yielding results. In […]
20
Jan
Jan
The last few years have been a true revolution in terms of discoveries and initiatives linked to the world of oligonucleotides, and all eyes and hopes continue to focus in the same direction in the new year 2023. It is clear that the research being carried out in the scientific world is yielding results. In […]
16
Jan
Jan
Cancer cachexia is a complex metabolic syndrome characterized by marked loss of body weight, anorexia, asthenia, sarcopenia, and anemia. It is the most common manifestation of advanced malignant cancer, leading to death. Approximately half of all cancer patients experience cachexia and the prevalence is over 80% in terminally ill patients, with cachexia being responsible for […]
10
Jan
Jan
Perhaps the definition is not the most accurate, but in reality a rare disease does nothing more than denominate a pathology that has not yet been studied, analyzed and against which there is, for the time being, no solution. The complexity of the processes to reach social development solutions for the improvement of patients’ quality […]
28
Dec
Dec
In the last days of the year, it is time to review everything we have done so far and plan for the coming months. The year 2022 has been very special for Oligofastx, because after the start date in October 2021 and the final resolution of CDTI on December 28, 2021, the project has become […]
22
Dec
Dec
The Oligofastx project covers all areas, from start to finish, of the process of developing oligonucleotides to fight several specific diseases: from design and preclinical research to production. Therefore, in this consortium, all the partners contribute their experience and knowledge in specific areas of action, thus completing a clear, consistent, coherent and results-oriented strategy. All […]
16
Dec
Dec
There is no doubt that oligonucleotide therapies aimed at providing answers and improving the quality of life of patients with certain rare diseases, which still have no solution, are a hopeful prospect. The path, already started with numerous initiatives, Oligofastx among them, is also a reality. But much research remains to be done, not only […]
International Biotechnology Day 2024, Uncategorized
Oligonucleotides, the language of life in small doses
12
Dec
Dec
A technological revolution can start with a key concept, the application of an equation or, often, with the development of a particular material. Steels, alloys, concretes, liquid fuels, semiconductors or polymers are examples that changed the history of mankind and today are ubiquitous in our lives. The pharmaceutical industry is no different. Thus, the ability […]